Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S., Richardson, Paul G., Popa McKiver, Mihaela, Jou, Ying-Ming, Yao, David, Das, Prianka, San-Miguel, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/
https://www.ncbi.nlm.nih.gov/pubmed/35960908
http://dx.doi.org/10.1200/JCO.21.02815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/
https://www.ncbi.nlm.nih.gov/pubmed/35960908
http://dx.doi.org/10.1200/JCO.21.02815

Ejemplares similares